Charles C. C. Owen, Jr., MD, MBA

Eli Lilly and Company

Poster(s):

• P2669 - Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn’s Disease
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P2670 - Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET